Navigation Links
Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
Date:7/30/2008

Clinical Program Leverages Quark's RNAi Technology

FREMONT, Calif., July 30 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced that its partner, Pfizer Inc, initiated patient dosing in a Phase II trial evaluating

PF-4523655 (RTP801i-14) in patients with diabetic macular edema (DME).

PF-4523655 is a novel siRNA drug candidate being co-developed by Quark and Pfizer. As part of the companies' Global Licensing Agreement, the successful commencement of the trial triggers a milestone payment to Quark from Pfizer, a small percentage of which is payable by Quark to Silence Therapeutics and Alnylam as technology license milestone payments.

The Phase II prospective, randomized, dose-ranging study is evaluating the safety and efficacy of PF-4523655 versus laser therapy in 160 DME patients at multiple centers worldwide. PF-4523655 was designed to inhibit Quark's proprietary target RTP801, a gene involved in abnormal blood vessel development and leakage in the eye. Under the companies' Global Licensing Agreement, Pfizer has exclusive development rights to siRNA-mediated therapies that inhibit RTP801 for ophthalmic and non-ophthalmic indications, while Quark is eligible for development and sales based milestone payments.

Elena Feinstein, Chief Scientific Officer of Quark, commented, "By targeting the RTP801 gene, PF-4523655 is differentiated from other therapeutics for the same ophthalmic indications. While many competitors target VEGF and its receptors, PF-4523655 inhibits abnormal blood vessel growth and leakage independently of the VEGF pathway, reduces inflammation and suppresses apoptosis. Therefore,

PF-4523655 is a siRNA therapeutic candidate with the potential to be efficacious when used as a monotherapy and in combination with existing VEGF-based therapies."

Shai Erlich, Chief Development
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
2. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
3. Quark Pharmaceuticals Appoints New Chief Medical Officer
4. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
5. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Idenix Pharmaceuticals Advances HCV Discovery Program to Clinic
8. Celator Pharmaceuticals Raises Series C Financing in Excess of $22.5 Million
9. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results and Provide a Clinical Program Update on August 7, 2008
10. Sound Pharmaceuticals Files Second IND with the FDA for the Prevention of Chemotherapy Induced Hearing Loss in Advanced Stage Cancer
11. Meditrina Pharmaceuticals, Inc. Opens Investigational New Drug (IND) Application for Phase IIb Clinical Trial With MPI-676 in Endometriosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... -- Capnia, Inc. (NASDAQ: CAPN ), ... on its proprietary Sensalyze™ Technology Platform for precision ... for the third quarter and nine months ended ... of our initial public offering (IPO), we are ... CoSense® commercial launch," said Anish Bhatnagar, M.D., Chief ...
(Date:12/19/2014)... 2014 Since last month,s FBI shutdown of ... as the leading online black market for illegal drugs ... its offering of drugs and other illegal items.  New ... did succeed in lowering the numbers of drugs and ... markets in August. But some new sites that have ...
(Date:12/19/2014)... China separating membrane market has witnessed robust development ... years, albeit as a later starter. In 2012, the size ... approximated RMB12 billion, with the proportion worldwide soaring to 16.3%. ... membrane market will continue its growth rate by around 20% ... will jump to roughly RMB25 billion. An integrated ...
Breaking Medicine Technology:Capnia Reports Third Quarter 2014 Financial Results 2Capnia Reports Third Quarter 2014 Financial Results 3Capnia Reports Third Quarter 2014 Financial Results 4Capnia Reports Third Quarter 2014 Financial Results 5Capnia Reports Third Quarter 2014 Financial Results 6Capnia Reports Third Quarter 2014 Financial Results 7Capnia Reports Third Quarter 2014 Financial Results 8Post Silk Road - Another Online Drug Den Now Dominates the DarkNet 2Post Silk Road - Another Online Drug Den Now Dominates the DarkNet 3Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 2Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 3
... 13, 2007--Active Biotech AB,(Stockholm:ACTI.ST) and Chelsea Therapeutics ... micro-dosing trial of an,I-3D compound. , The ... the pharmacokinetic,characteristics of the compound in humans. ... The study demonstrated that the selected I-3D ...
... 2007 /PRNewswire-FirstCall/ -- CV,Therapeutics, Inc. announced today that ... data from the Ranolazine Open Label,Experience (ROLE) program, ... to be safe and well,tolerated in patients with ... 3 clinical trials, and enrolled in the ROLE,program. ...
Cached Medicine Technology:Active Biotech's I-3D Micro-dosing Clinical Trial Concluded 2JACC Publishes Long-Term Safety and Tolerability Data from,Ranolazine Open Label Experience (ROLE) Program 2JACC Publishes Long-Term Safety and Tolerability Data from,Ranolazine Open Label Experience (ROLE) Program 3JACC Publishes Long-Term Safety and Tolerability Data from,Ranolazine Open Label Experience (ROLE) Program 4
(Date:12/22/2014)... 2014 Physicians in China are most ... treatment of non-Hodgkin’s lymphoma (NHL), according to a new ... healthcare consulting firm. MabThera is the only biologic available ... common form of NHL. , According to Kantar Health’s ... incidence of NHL in China has been growing and ...
(Date:12/22/2014)... Nevada (PRWEB) December 22, 2014 Only ... several southern and mid-western cities to have a battery ... TalkLocal ( http://www.talklocal.com ) is launching in ... local economy. , “A strong manufacturing sector is ... TalkLocal founder Gurpreet Singh explained, “and TalkLocal works with ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 Pasadena ... offering consultations for sleep apnea. Drowsy drivers are 15 ... drivers who are well-rested, and some experts believe that ... roads as intoxicated drivers. Unfortunately, millions of Americans may ... American Academy of Sleep Medicine, about 18 million Americans ...
(Date:12/22/2014)... Luxury Linen purveyor Peacock Alley once again joined ... logistics and support for one of Dallas’ largest holiday toy ... of giving back to the community in which it lives ... were Whataburger® and 99.5 The Wolf. , There is no ... to children who would otherwise not receive any is a ...
(Date:12/22/2014)... 21, 2014 A substantial percentage ... computed tomography (CT) to evaluate abnormal findings on ... cancer, according to a new study published online ... the findings show that radiologist recommendations for additional ... to patient care. , RAIs, which have grown ...
Breaking Medicine News(10 mins):Health News:Physicians in China See Most Significant Demand for MabThera Biosimilar 2Health News:Physicians in China See Most Significant Demand for MabThera Biosimilar 3Health News:TalkLocal Launches in Henderson Weeks Following New Megafactory, New Jobs Announcement 2Health News:Pasadena Dentist, Dr. Marine Martirosyan, Now Offers Consultations for Sleep Apnea 2Health News:Peacock Alley and Community Partners of Dallas Fulfill an Estimated 12,000 Holiday Wishes for Deserving Children 2Health News:RSNA: Radiologist Recommendations for Chest CT Have High Clinical Yield 2Health News:RSNA: Radiologist Recommendations for Chest CT Have High Clinical Yield 3
... cause permanent damage, researchers say , , FRIDAY, Feb. 8 ... and cause problems such as disturbed sleep, depression, anxiety ... , Researchers at Northwestern University,s Feinberg School of Medicine ... in people with chronic low back pain while they ...
... during the transition from high school through the first ... psychological implications, according to a report out of the ... good news is that during the first year of ... majority (78 percent) of the 870 incoming freshmen women ...
... NHS Choices ( http://www.nhs.uk ), the,online ,front ... news service to,help people make sense of the ... Behind the headlines, on NHS Choices,( http://www.nhs.uk/News/Pages/NewsIndex.aspx ), ... the news. The service explains the,facts behind newspaper ...
... - code situations in hospital parlance - easily expose common ... for children and also set up powerful incentives to ... a study from the Johns Hopkins Childrens Center. , ... and published in the January issue of Pediatrics, found sometimes ...
... 8 Symmetry Medical Inc.,(NYSE: SMA ), a ... industry and other medical markets, today announced it,will provide ... on,February 14, 2008 before the opening of the U.S. ... at 8:00 a.m. ET on,February 14, 2008., A ...
... Annual Event Raises Funds and Awareness for Chronic ... Feb. 8 The following release was,issued today ... Capital,Area:, WHO: Casino Night attracts a diverse ... medical and philanthropic communities in the Greater,Washington, DC ...
Cached Medicine News:Health News:Chronic Pain Harms Brain's Wiring 2Health News:A dangerous transition: High school to the first year of college 2Health News:A dangerous transition: High school to the first year of college 3Health News:A dangerous transition: High school to the first year of college 4Health News:Mock CPR 'codes' expose weaknesses in hospital emergency response for children 2Health News:Symmetry Medical to Provide Fourth Quarter 2007 General Business Update on February 14, 2008 2
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
Ethicon Endo-Surgery provides disposable handheld instruments that provide reliable, precise performance every time. Our handheld instruments come in 5mm and 10mm sizes....
... The Auto Suture™ ... inclusive of five (5) ... application in a variety ... urologic, colorectal and other ...
The ENDO MINI-RETRACT™ 5 mm instrument has application in a variety of gynecologic, abdominal, urologic, thoracic and endoscopic procedures for temporary retraction of tissue and small tubular ...
Medicine Products: